Apexium Financial LP Has $329,000 Stock Position in Bristol Myers Squibb Company $BMY

Apexium Financial LP trimmed its position in Bristol Myers Squibb Company (NYSE:BMY) by 21.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,099 shares of the biopharmaceutical company’s stock after selling 1,959 shares during the quarter. Apexium Financial LP’s holdings in Bristol Myers Squibb were worth $329,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its holdings in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the period. Vest Financial LLC grew its holdings in Bristol Myers Squibb by 73.5% during the first quarter. Vest Financial LLC now owns 16,912 shares of the biopharmaceutical company’s stock valued at $1,031,000 after purchasing an additional 7,166 shares during the period. Foster Group Inc. acquired a new position in Bristol Myers Squibb during the first quarter valued at approximately $257,000. Insight Advisors LLC PA grew its holdings in Bristol Myers Squibb by 8.9% during the first quarter. Insight Advisors LLC PA now owns 4,653 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 382 shares during the period. Finally, Procyon Advisors LLC grew its holdings in Bristol Myers Squibb by 52.3% during the first quarter. Procyon Advisors LLC now owns 28,423 shares of the biopharmaceutical company’s stock valued at $1,733,000 after purchasing an additional 9,763 shares during the period. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the subject of a number of analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Saturday, September 27th. Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research report on Tuesday, August 5th. Citigroup decreased their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, August 1st. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday. Finally, Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $56.38.

Bristol Myers Squibb Trading Down 0.7%

NYSE BMY opened at $45.39 on Friday. The stock has a market capitalization of $92.38 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 2.32 and a beta of 0.33. The stock’s 50 day moving average price is $46.36 and its two-hundred day moving average price is $48.58. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.5%. Bristol Myers Squibb’s payout ratio is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.